Physician profile
David I Malitz
NPI 1982671194
$12,336.22
in general payments reported to CMS, 2019-2025
34 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,895 · 2020: $912 · 2021: $2,210 · 2022: $1,482 · 2023: $1,402 · 2024: $2,816 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,941 · Long Term Medical Supply Or Device Loan: $1,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,940.66 |
| Long Term Medical Supply Or Device Loan | $1,896.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,456.38 | 2023-2025 | Scoutpro Osmolarity System, Xiidra, Miebo |
| Johnson & Johnson Surgical Vision, INC. | $1,421.98 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Allergan, INC. | $989.09 | 2019-2022 | |
| Alcon Vision LLC | $972.19 | 2019-2025 | Rocklatan, Centurion, Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $676.41 | 2019-2021 | |
| Abbvie INC. | $626.05 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $602.37 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $444.21 | 2019-2022 | |
| Harrow Eye, LLC | $408.71 | 2023-2025 | Vevye, Iheezo |
| Sun Pharmaceutical Industries INC. | $339.15 | 2019-2023 | Cequa |
| Kala Pharmaceuticals, INC. | $328.67 | 2019-2021 | |
| Biotissue Holdings INC. | $291.51 | 2019-2025 | |
| Eyepoint US, INC. | $290.31 | 2020-2021 | |
| Rxsight INC | $270.58 | 2021-2023 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Aerie Pharmaceuticals, INC. | $265.41 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $264.05 | 2024-2025 | Xdemvy |
| Mallinckrodt Enterprises LLC | $259.32 | 2019 | |
| New World Medical,INC. | $240.66 | 2021-2024 | Streamline, Kahook Dual Blade, Clearpath |
| Ivantis, INC | $189.60 | 2021 | |
| Amgen INC. | $170.48 | 2024-2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $121.81 | 2023 | Syfovre |
| Mallinckrodt Hospital Products INC. | $104.17 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $93.39 | 2024 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $88.47 | 2025 | Izervay |
| Regeneron Pharmaceuticals, INC. | $75.00 | 2023 | Eylea |
| Regeneron Healthcare Solutions, INC. | $70.90 | 2019 | |
| Omeros Corporation | $51.75 | 2019 | |
| Ocular Therapeutix, INC. | $41.32 | 2021-2022 | |
| Sight Sciences, INC. | $38.67 | 2022-2025 | Sion Surgical Instrument, Omni Surgical System |
| Carl Zeiss Meditec, INC. | $36.11 | 2023 | |
| Horizon Therapeutics Plc | $32.47 | 2022 | |
| Shire North American Group INC | $28.16 | 2019 | |
| Medline Industries LP | $26.21 | 2024 | |
| Optos, INC. | $20.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Malitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.